Replimune Group develops next-generation oncolytic immunotherapies aimed at improving direct anti-tumor effects of selective virus replication and boosting immune responses to tumor antigens. Its Immulytic™ platform is designed to maximize systemic immune activation through viral-mediated immunogenic tumor cell killing and delivery of immune-activating proteins to tumors and draining lymph nodes. The company’s lead product is RP1, and Replimune is advancing additional candidates from the Immulytic™ platform. Replimune intends to use its recent financing proceeds to generate human proof-of-concept data for RP1 across multiple tumor types. The company is led by Dr. Robert Coffin (CEO) and Howard Kaufman (CMO). The business is based in Woburn, Massachusetts. Replimune is developing proprietary oncolytic immunotherapies intended to enhance direct anti-tumor effects of selective virus replication and boost immune responses to tumor antigens. The company intends to progress these immunotherapies through clinical trials and to combine them with checkpoint blockade at an early stage of development. Replimune also plans to pursue a partnering strategy with companies that have approved or experimental checkpoint blockade or other complementary immuno-oncology drugs. Founded in April 2015, the company is Oxford, UK–based and has a significant presence in Cambridge, MA. Led by CEO Robert Coffin, Replimune emphasized advancing its programs into early clinical development. In conjunction with the financing, new board members from lead and participating investors will join the company.

Total raised

$85M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2017